Active, Not Recruiting
An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies - CA209-908
Updated: 29 March, 2021 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Active, Not Recruiting
Treatment Options
Inclusion Criteria: For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com - Children and adolescents diagnosed with either: - Diffuse Intrinsic Pontine Glioma (DIPG), in first-line, after completion of standard radiotherapy - High Grade Glioma (HGG), recurrent or progressive - Medulloblastoma, recurrent or progressive - Ependymoma, recurrent or progressive - Other high-grade tumors of the central nervous system, recurrent or progressive - Lansky play score (LPS) for =< 16 years of age or Karnofsky performance scale (KPS) for > 16 years of age assessed within two weeks of enrollment must be >= 60 - A tumor sample must be available for submission to central laboratory [not required for DIPG] Exclusion Criteria: - Participants with active, known or suspected autoimmune disease - Participants unable to taper steroids due to ongoing mass effect - Participants with low-grade gliomas or tumors of unknown malignant potential - Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors) Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
